The U.S. Food and Drug Administration granted Breakthrough Therapy Designation to Cogent Biosciences’ bezuclastinib plus sunitinib combination for patients with gastrointestinal stromal tumor (GIST) who have progressed on imatinib. The designation follows the Phase 3 PEAK trial, which demonstrated a median progression‑free survival of 16.5 months for the combination versus 9.2 months for sunitinib alone, a 50 % reduction in the risk of disease progression or death (hazard ratio 0.50, 95 % CI 0.39–0.65). The trial also reported objective response rates of 46 % for the combination compared with 26 % for sunitinib alone, and the safety profile was consistent with known sunitinib toxicity, with no new safety signals.
The Breakthrough Therapy Designation is a significant regulatory milestone that signals the FDA’s recognition of the combination’s potential to substantially improve outcomes for a patient group that has had no new treatment options in over two decades. By qualifying for the FDA’s Real‑Time Oncology Review program, Cogent can engage in accelerated, iterative dialogue with regulators, potentially shortening the time to approval and bringing the therapy to patients sooner.
Cogent plans to submit a full New Drug Application under the Real‑Time Oncology Review program in April 2026. The company will also present the complete PEAK trial data in the first half of 2026 and is launching a Phase 2 study of the combination in first‑line exon 9 GIST patients expected to begin mid‑2026. These steps position Cogent to capture a sizable share of the GIST market, which is dominated by sunitinib, regorafenib, and ripretinib, and to address unmet resistance mechanisms that limit current therapies.
Andrew Robbins, President and CEO of Cogent, said the Breakthrough Therapy Designation “recognizes the potential of bezuclastinib to overcome resistance mutations that limit the effectiveness of existing second‑line therapies and could become the first new treatment option for imatinib‑resistant GIST in more than 20 years.” He added that the company remains focused on delivering a safe, effective therapy while engaging closely with the FDA to expedite the review process.
The designation underscores the strategic importance of the combination therapy and signals confidence from regulators that the clinical data support a meaningful benefit over current standards of care. Cogent’s planned NDA submission and ongoing clinical development efforts reinforce its commitment to advancing this therapy through the regulatory pipeline and ultimately expanding treatment options for patients with GIST.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.